# Seminar 19: Immunizations and Prevention ## Unit 3: Pediatrics Clerkship --- ## Learning Objectives 1. Apply the routine childhood immunization schedule from birth through adolescence using current CDC/ACIP recommendations 2. Recognize true contraindications and precautions to vaccination and differentiate them from common misconceptions 3. Address vaccine hesitancy using evidence-based communication strategies and motivational interviewing techniques 4. Describe catch-up vaccination principles including minimum intervals and accelerated schedules for unvaccinated children 5. Identify special populations requiring modified vaccination schedules including preterm infants and immunocompromised patients 6. Apply principles of anticipatory guidance and preventive care across pediatric well-child visits --- ## Lecture Outline ### Section 1: Principles of Immunization Immunization represents one of the most significant public health achievements in history, preventing millions of deaths and disabilities from infectious diseases through stimulation of the immune system to provide protection against specific pathogens. Active immunity develops when the individual's own immune system responds to antigen exposure, whether through natural infection or vaccination, creating memory cells that provide durable protection against future encounters with the pathogen. Passive immunity involves transfer of preformed antibodies from an external source, such as transplacental transfer of maternal immunoglobulins or administration of immune globulin preparations. Understanding these fundamental immunologic principles provides the foundation for vaccine administration, timing, and catch-up scheduling. Vaccine types are classified by the nature of the antigen and the method of immune stimulation employed. Live attenuated vaccines contain weakened but replication-competent organisms that stimulate immune responses similar to natural infection, including MMR, varicella, rotavirus, and the intranasal influenza vaccine. Inactivated vaccines contain killed whole organisms or components that cannot replicate, including inactivated polio vaccine and hepatitis A vaccine. Subunit and conjugate vaccines contain specific protein or polysaccharide components, with conjugate vaccines linking polysaccharides to carrier proteins to enhance immunogenicity in young children, as used in Hib, pneumococcal, and meningococcal vaccines. mRNA vaccines represent a newer platform that provides genetic instructions for cells to produce viral proteins, as used in COVID-19 vaccines. Herd immunity, also known as community immunity, describes the indirect protection afforded to unvaccinated individuals when a sufficient proportion of the population is immune to an infectious disease. The threshold for herd immunity varies by disease based on transmissibility, with highly contagious diseases like measles requiring approximately 95% population immunity to prevent sustained transmission. This concept has profound implications for protecting individuals who cannot be vaccinated, including infants too young for certain vaccines, individuals with contraindications, and immunocompromised patients. When vaccination rates fall below herd immunity thresholds, outbreaks occur even in communities where the majority of individuals are vaccinated. Vaccine effectiveness describes real-world performance, which may differ from efficacy measured in controlled clinical trials due to various factors affecting vaccine response and disease transmission. Duration of protection varies by vaccine, with some providing lifelong immunity after a complete series while others require boosters to maintain protection. Factors affecting vaccine response include the recipient's age, immune status, and nutritional state, as well as proper vaccine storage and handling. Breakthrough infections can occur in vaccinated individuals, particularly when circulating strains differ from vaccine strains or when immunity wanes over time, but vaccinated individuals typically experience less severe disease. Panel A: Diagram illustrating the difference between active and passive immunity with cellular and antibody response pathways. Panel B: Visual comparison of different vaccine types showing live attenuated, inactivated, subunit, conjugate, and mRNA platforms with their characteristics. Panel C: Herd immunity threshold diagram showing how immunized populations protect vulnerable unvaccinated individuals. Panel D: Graph showing vaccine efficacy versus effectiveness with factors that influence real-world performance. --- ### Section 2: Routine Childhood Schedule - Birth to 6 Years The childhood immunization schedule begins at birth with hepatitis B vaccine, which should be administered within the first 24 hours of life regardless of maternal hepatitis B surface antigen status. For infants born to hepatitis B surface antigen-positive mothers, hepatitis B immune globulin should be administered concurrently with the first vaccine dose to provide immediate passive protection while the infant's immune response develops. The birth dose establishes early protection against a virus that can cause chronic infection and hepatocellular carcinoma when acquired perinatally. Subsequent doses are typically administered at 1-2 months and 6-18 months to complete the primary series. The 2-month, 4-month, and 6-month visits represent critical timepoints for primary immunization with multiple vaccines. DTaP (diphtheria, tetanus, acellular pertussis) is administered at 2, 4, and 6 months, providing protection against three serious bacterial diseases. Haemophilus influenzae type b vaccine prevents invasive disease including meningitis and epiglottitis, with the schedule varying slightly by product. Inactivated polio vaccine is given at 2 and 4 months with the third dose at 6-18 months. Pneumococcal conjugate vaccine (PCV13 or PCV15) protects against the leading cause of bacterial meningitis and pneumonia in young children. Rotavirus vaccine, given at 2 and 4 months (and 6 months depending on the product), prevents the leading cause of severe gastroenteritis in infants. The 12-18 month visits introduce several new vaccines and complete others with booster doses. MMR (measles, mumps, rubella) vaccine is first administered at 12-15 months, providing protection against three highly contagious viral diseases. Varicella vaccine is similarly given at 12-15 months to prevent chickenpox and its complications. Hepatitis A vaccine is started at 12-23 months with a two-dose series separated by at least 6 months. Fourth doses of DTaP, Hib, and PCV13/15 are administered at 15-18 months to boost waning immunity from the primary series. The timing of these vaccines reflects the waning of maternal antibodies and the child's developing immune competence. The 4-6 year visit, typically before kindergarten entry, completes the preschool immunization series with booster doses. The fifth dose of DTaP is administered at 4-6 years, providing protection through the elementary school years until the Tdap booster in adolescence. The fourth dose of IPV completes the polio series. Second doses of MMR and varicella vaccines are given to ensure seroconversion in the small percentage who do not respond to the first dose and to boost immunity before school entry. These vaccinations often coincide with school entry requirements, though medical exemptions and non-medical exemptions (where permitted) affect enforcement. Panel A: Timeline infographic showing birth dose through 24-month vaccine administration with color-coded vaccines. Panel B: Illustration of diseases prevented by 2-4-6 month vaccines with clinical photographs of each condition. Panel C: Visual reminder of 12-18 month vaccine additions with MMR, varicella, and hepatitis A highlighted. Panel D: School entry immunization checklist showing 4-6 year requirements with typical state mandates. --- ### Section 3: Adolescent and Annual Vaccines The 11-12 year visit represents an important platform for adolescent immunization, introducing vaccines that provide protection through adolescence and adulthood. Tdap vaccine replaces DTaP, providing a booster of tetanus and diphtheria toxoids with reduced-dose acellular pertussis, transitioning from the childhood to adult formulation. Human papillomavirus vaccine is routinely recommended at 11-12 years, with a two-dose schedule for those initiating before age 15 and a three-dose schedule for those starting at 15 or older. Meningococcal ACWY vaccine provides protection against four serogroups of Neisseria meningitidis that cause invasive meningococcal disease, with a booster recommended at age 16. Human papillomavirus vaccine represents one of the most significant cancer prevention opportunities available, preventing infections responsible for cervical, anal, oropharyngeal, penile, vaginal, and vulvar cancers. The vaccine is recommended for all adolescents regardless of sex, as HPV-related cancers affect both males and females. Vaccination before sexual debut maximizes effectiveness, though the vaccine provides benefit even after potential exposure by protecting against HPV types not yet acquired. Completion of the series before age 15 requires only two doses separated by 6-12 months, compared to three doses for those beginning at 15 or older. Meningococcal vaccination in adolescents includes both ACWY conjugate vaccines and serogroup B vaccines, though with different recommendations. MenACWY is routinely recommended at age 11-12 with a booster at age 16, capitalizing on the increased risk of meningococcal disease in adolescence and young adulthood. Meningococcal B vaccine is recommended based on shared clinical decision-making for adolescents aged 16-23, with preferred administration at 16-18 years. Certain high-risk individuals, including those with complement deficiencies, functional or anatomic asplenia, or those exposed during outbreaks, should receive both MenACWY and MenB vaccines according to specific schedules. Influenza vaccine is recommended annually for all individuals 6 months and older, with particular importance in pediatric populations due to the burden of influenza morbidity and mortality in children. Children receiving influenza vaccine for the first time before age 9 should receive two doses separated by at least 4 weeks to ensure adequate immune response. Both inactivated influenza vaccine (injection) and live attenuated influenza vaccine (intranasal) are available, with LAIV approved for healthy individuals aged 2-49 years who are not pregnant or immunocompromised. COVID-19 vaccines follow evolving recommendations based on circulating variants and vaccine availability, with current guidance available through CDC. Panel A: Adolescent immunization platform showing Tdap, HPV, and meningococcal vaccines recommended at 11-12 years. Panel B: HPV-related cancer statistics showing burden of disease and prevention potential with vaccine coverage. Panel C: Meningococcal disease epidemiology showing age-related incidence and vaccine timing rationale. Panel D: Influenza vaccine algorithm showing dose determination based on age and vaccination history. --- ### Section 4: Contraindications and Precautions True contraindications to vaccination are relatively rare and must be distinguished from misconceptions and inappropriate deferrals that leave children unprotected. Severe allergic reaction (anaphylaxis) to a previous dose of a vaccine or to a vaccine component represents a contraindication to subsequent doses of that vaccine or vaccines containing the same component. Encephalopathy within 7 days of a pertussis-containing vaccine is a contraindication to further pertussis vaccination, though DTaP may be replaced with DT to continue tetanus and diphtheria protection. Live vaccines are contraindicated in significantly immunocompromised individuals and during pregnancy due to theoretical risks of disseminated infection and fetal harm. Common misconceptions about vaccine contraindications result in missed opportunities for immunization and leave children vulnerable to preventable diseases. Mild illness with or without low-grade fever is not a contraindication to vaccination; children may be immunized when they have colds, otitis media, or other minor illnesses. Current antibiotic therapy does not affect vaccine response and is not a reason to defer vaccination. Prematurity is not a contraindication; preterm infants should be vaccinated according to chronologic age at full doses. Breastfeeding is compatible with all childhood vaccines, including live vaccines. Family history of adverse reactions does not contraindicate vaccination in the individual patient. Precautions differ from contraindications in that they represent conditions under which vaccination should be carefully considered but may proceed if benefits outweigh risks. Moderate-to-severe acute illness suggests deferral until recovery to avoid confusing symptoms of illness with vaccine adverse events and to ensure optimal immune response. Recent receipt of blood products may interfere with immune response to live vaccines, requiring specific waiting intervals. History of Guillain-Barre syndrome within 6 weeks of a previous dose of influenza vaccine warrants discussion of risks and benefits. Thrombocytopenia or bleeding disorders require consideration of the risk of intramuscular injection. Live vaccine administration requires particular attention to spacing and special considerations. Live injectable vaccines (MMR, varicella) that are not given simultaneously should be separated by at least 4 weeks to avoid interference. Live oral vaccines (rotavirus) have fewer spacing requirements as they replicate in the gastrointestinal tract. Immunocompromised patients should not receive live vaccines, though the definition of immunocompromise varies by condition and treatment. Household contacts of immunocompromised individuals should receive inactivated influenza vaccine rather than LAIV to avoid potential transmission of vaccine-strain virus. Panel A: True contraindications decision tree with specific vaccine considerations for each scenario. Panel B: Common misconceptions visual with "Not a contraindication" labels for frequently misapplied situations. Panel C: Precaution assessment flowchart showing risk-benefit decision process. Panel D: Live vaccine spacing diagram showing minimum intervals and special considerations. --- ### Section 5: Vaccine Hesitancy and Communication Vaccine hesitancy represents a spectrum of attitudes ranging from complete acceptance to complete refusal, with many parents occupying intermediate positions characterized by concerns, questions, or preferences for modified schedules. Understanding the roots of vaccine hesitancy is essential for effective communication; concerns may relate to perceived vaccine safety, beliefs about natural immunity, distrust of pharmaceutical companies or government, or specific concerns based on misinformation. The goal is not to win arguments but to build trust and provide accurate information that allows parents to make informed decisions. Dismissing concerns or becoming defensive is counterproductive and may push hesitant parents further toward refusal. Evidence-based communication strategies begin with listening to understand the specific concerns each parent holds. The presumptive approach, stating vaccinations as the normal course of action rather than asking whether parents want to vaccinate, has been shown to increase acceptance rates. For example, "Today we'll do the vaccines that are due" is more effective than "Do you want to get vaccines today?" When concerns are raised, empathetic acknowledgment validates the parent's desire to protect their child before providing evidence-based information. Personal recommendations from healthcare providers carry significant weight; statements like "I recommend this vaccine" or "I vaccinated my own children" build trust. Addressing common specific concerns requires accurate information delivered with empathy and respect. The thoroughly debunked link between MMR and autism should be addressed with reference to multiple large studies demonstrating no association, while acknowledging the understandable desire to find explanations for children's developmental challenges. Concerns about "too many vaccines" can be addressed with evidence that the modern schedule exposes children to far fewer antigens than historical schedules despite more vaccines, and that the immune system can easily handle the antigens in vaccines. The preferability of natural immunity must be weighed against the risks of acquiring natural infection, which may cause severe disease, complications, or death. Alternative schedules and continued engagement maintain the relationship when full vaccination is refused. Delayed or alternative schedules are not recommended as they leave children unprotected during vulnerable periods, but some parents may accept partial or delayed vaccination rather than none. Documentation of informed refusal protects the provider and creates an opportunity to revisit the decision at subsequent visits. Continuing to offer vaccines at every visit maintains the relationship and provides opportunities as parental attitudes may evolve over time. Dismissing families from practice is controversial and may reduce access to medical care and future opportunities for vaccination. Panel A: Vaccine hesitancy spectrum diagram showing positions from complete acceptance to complete refusal with intervention approaches. Panel B: Presumptive versus participatory approach comparison with sample language for each. Panel C: Evidence summary for common concerns including autism, ingredient safety, and immune system capacity. Panel D: Motivational interviewing technique examples with provider responses to typical hesitancy statements. --- ### Section 6: Catch-Up Vaccination Catch-up vaccination is required when children present with incomplete immunization histories, whether due to missed well-child visits, vaccine refusal that parents now wish to reverse, international adoption, or immigration from areas with different vaccination schedules. The fundamental principle is that vaccine doses already received count; series do not need to be restarted when intervals between doses exceed recommendations. However, minimum intervals between doses must be maintained, as shorter intervals may result in inadequate immune response. The catch-up schedule, published annually by ACIP, provides specific guidance on minimum intervals and accelerated schedules for each vaccine. Minimum intervals between doses ensure adequate immune response and cannot be shortened regardless of desire to rapidly complete the series. For DTaP, the minimum interval between doses 1, 2, and 3 is 4 weeks, with a minimum of 6 months between doses 3 and 4, and 6 months between doses 4 and 5. Hepatitis B requires a minimum of 4 weeks between doses 1 and 2, and 8 weeks between doses 2 and 3, with dose 3 not given before 24 weeks of age. MMR doses must be separated by at least 4 weeks. PCV and Hib catch-up schedules depend on current age and number of doses already received, with fewer doses required when catch-up begins at older ages. Catch-up for unvaccinated children and adolescents follows specific age-based recommendations. Children younger than 7 years receive DTaP, while those 7 and older receive Tdap for the first dose followed by either Td or Tdap for subsequent doses. Hib and PCV catch-up is not needed for healthy children who have reached age 5, as the risk of invasive disease decreases substantially. Rotavirus vaccine cannot be initiated after age 15 weeks and cannot be completed after age 8 months due to age-specific efficacy and safety considerations. IPV, hepatitis B, hepatitis A, MMR, and varicella catch-up can proceed at any age following catch-up schedules. Documentation of prior vaccination is the gold standard for determining what vaccines are needed. When records are unavailable, vaccination history should be considered unknown, and appropriate catch-up should begin. However, serologic testing can confirm immunity to some vaccine-preventable diseases, potentially reducing the need for repeated vaccination. Serologic testing is particularly useful for internationally adopted children whose vaccination histories may be uncertain or inaccurate. School immunization requirements vary by state but generally require documentation of vaccination or immunity; clinicians should be familiar with local requirements to ensure children can attend school. Panel A: Minimum interval chart showing required spacing between doses for major vaccines. Panel B: Age-based catch-up algorithm showing different pathways for children under 7 versus 7 and older. Panel C: Decision tree for managing children with unknown or uncertain vaccination history. Panel D: School entry requirements map showing variation in exemption policies by state. --- ### Section 7: Special Populations Preterm infants require special consideration in vaccination timing but should generally receive vaccines according to chronologic age rather than adjusted gestational age. The full recommended dose should be given regardless of prematurity, as divided or reduced doses provide inadequate protection. The birth dose of hepatitis B may be deferred until hospital discharge or 1 month of age for medically stable infants weighing less than 2000 grams born to hepatitis B surface antigen-negative mothers. Rotavirus vaccine may be given if the infant is at least 6 weeks old and medically stable. Preterm infants may have slightly lower initial antibody responses to some vaccines but achieve protective levels after completing the recommended series. Immunocompromised patients require individualized vaccination planning based on the nature and degree of immunocompromise. Live vaccines are generally contraindicated in significantly immunocompromised individuals due to the risk of disseminated vaccine-strain infection. However, the definition of significant immunocompromise varies by condition: patients with HIV may receive MMR and varicella vaccines if CD4 counts are adequate, while patients receiving high-dose corticosteroids should delay live vaccines until steroid doses are reduced. Inactivated vaccines are safe in immunocompromised patients but may be less immunogenic; some conditions warrant additional doses or more frequent boosters. Household contacts of immunocompromised patients should be fully vaccinated to provide indirect protection. Patients with asplenia, sickle cell disease, complement deficiencies, and cochlear implants require additional vaccinations against encapsulated organisms. Pneumococcal vaccination should include both conjugate (PCV13 or PCV15) and polysaccharide (PPSV23) vaccines with specific timing intervals. Meningococcal vaccination should include both ACWY and B serogroup vaccines with boosters every 5 years. Hib vaccine may be recommended for previously unvaccinated individuals with certain conditions. These additional vaccines address the increased susceptibility to invasive bacterial disease that characterizes these conditions. Travelers require assessment of routine vaccinations as well as travel-specific recommendations based on destination and activities. Routine childhood vaccinations should be reviewed and updated, with accelerated schedules used when departure is imminent. Hepatitis A vaccine should be given to all travelers to endemic areas regardless of prior vaccination status. Additional travel vaccines including typhoid, yellow fever, Japanese encephalitis, and rabies may be indicated depending on specific itinerary and activities. Malaria prevention requires chemoprophylaxis rather than vaccination, as no malaria vaccine is currently available for travelers. Consultation with a travel medicine specialist is recommended for complex itineraries or high-risk travelers. Panel A: Preterm infant vaccination timeline showing chronologic age-based schedule with special considerations. Panel B: Immunocompromised patient vaccine decision matrix based on condition and degree of immunosuppression. Panel C: Additional vaccine recommendations for asplenic patients with timing and booster schedules. Panel D: Travel vaccine decision algorithm based on destination risk categories and departure timing. --- ### Section 8: Vaccine Safety and Adverse Events Common vaccine side effects are generally mild and self-limited, reflecting normal immune activation rather than injury. Local reactions at the injection site including pain, redness, and swelling are common across vaccine types and typically resolve within 24-48 hours. Systemic symptoms including fever, irritability, and fatigue occur with varying frequency depending on the vaccine and may reflect cytokine release associated with immune response. Parents should be counseled about expected side effects and provided with guidance on symptom management, including acetaminophen or ibuprofen for fever and discomfort. These common reactions do not contraindicate future doses of the same vaccine. Rare adverse events require surveillance and investigation to distinguish coincidental events from true vaccine-caused complications. Febrile seizures may occur following vaccines that commonly cause fever, particularly MMR and DTaP, but are typically benign and do not increase the risk of epilepsy. Anaphylaxis can occur with any vaccine but is very rare, occurring at rates of approximately 1-2 per million doses administered; observation periods after vaccination allow for recognition and treatment. Intussusception is associated with rotavirus vaccines at a rate of approximately 1-2 additional cases per 100,000 vaccinated infants. Injection site injuries can occur with improper technique or anatomic variation. The Vaccine Adverse Event Reporting System (VAERS) serves as a passive surveillance system for monitoring vaccine safety signals. Healthcare providers are required to report certain adverse events following vaccination and encouraged to report any events they consider clinically significant. VAERS reports can generate hypotheses about potential associations between vaccines and adverse events but cannot prove causation, as reported events may be coincidental. When signals are detected, controlled epidemiologic studies are conducted to determine whether true associations exist. Public access to VAERS data has led to misinterpretation, as raw reports do not account for background rates of events or confounding factors. The National Vaccine Injury Compensation Program (VICP) provides a no-fault system for compensating individuals injured by covered vaccines. The program was established in 1986 to maintain vaccine supply by protecting manufacturers from litigation while ensuring compensation for the rare individuals who experience vaccine injuries. The Vaccine Injury Table lists specific injuries and time intervals that are presumed to be vaccine-caused, facilitating compensation without requiring proof of causation. Petitions must be filed within 3 years of injury onset. Clinicians should provide Vaccine Information Statements before each vaccination as required by law, documenting vaccine type, manufacturer, lot number, and administration site. Panel A: Common vaccine side effects chart with expected frequencies and duration by vaccine type. Panel B: Rare adverse event investigation pathway from VAERS signal detection to epidemiologic study. Panel C: VAERS reporting requirements and limitations explained with emphasis on hypothesis generation versus causation. Panel D: VICP process overview showing petition timeline, Vaccine Injury Table, and compensation pathways. --- ### Section 9: Anticipatory Guidance Anticipatory guidance represents proactive counseling provided at preventive care visits to help parents address developmental stages and safety concerns before problems arise. Safety counseling content varies by age and reflects the leading causes of injury at each developmental stage. Newborn safety focuses on safe sleep practices including supine positioning, firm sleep surfaces, and room-sharing without bed-sharing to reduce SIDS risk, along with proper car seat installation and the dangers of shaking. Infant safety addresses choking hazards as solid foods are introduced, fall prevention as motor skills develop, burn prevention, and water safety. Toddler counseling includes poison prevention, gun storage safety, ongoing car seat use, and pedestrian and driveway safety. Nutrition guidance supports healthy growth and development while establishing lifelong eating patterns. Exclusive breastfeeding is recommended for approximately 6 months, with continued breastfeeding for 1 year or longer alongside complementary foods. Solid food introduction typically begins at 4-6 months when developmental readiness cues are present. Iron-fortified cereals provide needed supplementation as iron stores are depleted. Juice should be limited to no more than 4 ounces daily for young children due to association with dental caries and obesity. Whole milk is introduced at 12 months and maintained until age 2 to support brain development. Adolescent nutrition counseling addresses calcium and iron needs, eating disorders, and healthy weight maintenance. Developmental promotion counseling supports cognitive, motor, and social-emotional development. Tummy time for infants strengthens neck and shoulder muscles needed for motor milestones. Reading aloud from early infancy supports language development, with the American Academy of Pediatrics recommending literacy promotion at all well-child visits. Play, particularly unstructured play, supports creativity, problem-solving, and social skills. Parental responsiveness to infant cues promotes secure attachment and emotional regulation. School-age counseling addresses academic support, extracurricular activities, and developing independence while maintaining connection. Screen time recommendations reflect emerging evidence about the effects of digital media on child development. For children younger than 18 months, video chat is the only recommended screen use. From 18-24 months, high-quality programming may be introduced with parent co-viewing and interaction. Children aged 2-5 years should have no more than 1 hour per day of high-quality programming. For children 6 and older, consistent limits should be established while ensuring that screen time does not displace sleep, physical activity, or in-person social interaction. Modeling healthy media use and establishing media-free times and zones support family implementation of these recommendations. Panel A: Age-based safety counseling checklist from newborn through adolescence with key topics for each stage. Panel B: Nutrition milestone timeline showing feeding transitions from birth through early childhood. Panel C: Developmental promotion activities by age with emphasis on reading, play, and responsiveness. Panel D: Screen time recommendations visual with age-specific limits and quality considerations. --- ### Section 10: Preventive Care Visits The periodicity schedule, as outlined by Bright Futures and the American Academy of Pediatrics, establishes recommended timing for well-child visits throughout childhood and adolescence. Infancy visits occur at newborn, 3-5 days, and 1, 2, 4, 6, 9, and 12 months of age, reflecting the rapid developmental changes and vaccination schedule of the first year. Early childhood visits occur at 15, 18, 24, and 30 months, then annually at 3 and 4 years. Middle childhood through adolescence features annual visits from ages 5 through 21 years. This schedule provides opportunities for developmental surveillance, screening, immunization, and anticipatory guidance at developmentally appropriate intervals. Screening tests identify conditions where early detection improves outcomes, with recommendations based on evidence of screening effectiveness. Newborn metabolic screening and hearing screening are performed in the birth hospitalization. Vision screening occurs at 3-5 years using age-appropriate methods, with continued assessment throughout childhood. Developmental screening using validated instruments (ASQ, PEDS) is recommended at 9, 18, and 30 months, with autism-specific screening at 18 and 24 months. Lead screening is recommended at 1 and 2 years of age in high-risk populations or universally based on local prevalence. Anemia screening occurs at 9-12 months, with additional screening for at-risk adolescent females. Universal lipid screening is recommended between ages 9-11 years. Depression screening using validated instruments begins at age 12. Components of the well-child visit extend beyond immunizations to encompass comprehensive preventive care. The health history captures interval health concerns, developmental progress, and family psychosocial factors. Physical examination includes complete assessment with particular attention to growth parameters tracked on age-appropriate growth charts. Developmental surveillance occurs at every visit, with formal screening at designated ages. Vision and hearing assessment ensures sensory development necessary for learning. Oral health assessment begins with tooth eruption, with fluoride varnish applied at dental and medical visits. Anticipatory guidance addresses age-appropriate topics in safety, nutrition, development, and behavior. Documentation of preventive care ensures continuity and facilitates quality improvement. Growth parameters plotted on age- and sex-appropriate charts allow tracking of growth patterns over time, with deviations prompting evaluation for underlying conditions. Developmental milestones documented at each visit create a longitudinal record of progress and identify concerns early. Vaccination records must be complete and accurate, meeting school entry requirements and facilitating catch-up when needed. Counseling topics addressed should be documented to avoid repetition and ensure comprehensive coverage over time. Standardized preventive care templates in electronic health records support consistent documentation and care delivery. Panel A: Bright Futures periodicity schedule timeline showing visit frequency from birth through adolescence. Panel B: Developmental screening timeline showing specific instruments and recommended ages. Panel C: Well-child visit component checklist with standard elements for each visit type. Panel D: Growth chart interpretation guide showing normal variation, crossing percentiles, and concerning patterns. --- ## Summary - Vaccine types include live attenuated (MMR, varicella, rotavirus), inactivated (IPV, hepatitis A), subunit/conjugate (DTaP, Hib, PCV), and mRNA platforms with different mechanisms of immune stimulation - Hepatitis B vaccine is given within 24 hours of birth; the 2-4-6 month series includes DTaP, Hib, IPV, PCV, rotavirus, and hepatitis B - The 12-18 month visits add MMR, varicella, and hepatitis A vaccines along with boosters of DTaP, Hib, and PCV - Adolescent vaccines at 11-12 years include Tdap, HPV (2 or 3 doses based on age at initiation), and MenACWY - True contraindications include severe allergic reaction to previous dose or component, encephalopathy after pertussis vaccine, and live vaccines in significantly immunocompromised patients - Mild illness, antibiotic use, prematurity, and breastfeeding are NOT contraindications to vaccination - Vaccine hesitancy is addressed through presumptive communication, empathetic listening, evidence-based responses, and strong personal recommendations - Catch-up vaccination follows minimum intervals that cannot be shortened; prior doses count and series need not be restarted - Immunocompromised patients generally should not receive live vaccines; patients with asplenia need additional pneumococcal and meningococcal vaccines - Well-child visits follow the Bright Futures periodicity schedule with age-specific screening, immunization, and anticipatory guidance at each visit --- ## Key Terms | Term | Definition | |------|------------| | Live Attenuated Vaccine | Vaccine containing weakened but replication-competent organisms that stimulate immune responses similar to natural infection | | Conjugate Vaccine | Vaccine linking polysaccharide antigens to protein carriers to enhance immunogenicity, particularly important for young children | | Herd Immunity | Indirect protection of unvaccinated individuals when a sufficient proportion of the population is immune to an infectious disease | | VAERS | Vaccine Adverse Event Reporting System, a passive surveillance system for monitoring potential vaccine safety signals | | VICP | National Vaccine Injury Compensation Program, a no-fault system for compensating individuals injured by covered vaccines | | Bright Futures | American Academy of Pediatrics guidelines for preventive care including recommended visit periodicity and content | | Presumptive Communication | Communication approach stating vaccinations as the normal course of action rather than presenting as optional | | Minimum Interval | Shortest allowable time between vaccine doses to ensure adequate immune response; cannot be shortened | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*